Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
Best FDA-Approved GLP-1 on Prime Therapeutics Formulary (2026): Verified Tiers, PA Decoder & Your Next Move
Published: · Last reviewed:
•By The RX Index Editorial Team
The fastest honest answer. The best FDA-approved GLP-1 on Prime Therapeutics formulary to verify first is usually Zepbound or Wegovy if your plan covers weight-loss medications. Prime reports parity coverage for Wegovy and Zepbound on its national weight-loss formularies — neither one is “preferred” over the other the way CVS Caremark forces members to start with Wegovy. The catch we have to be straight about: about 20% of Prime Therapeutics covered lives are in a benefit plan that covers weight-loss medications, per Prime's chief clinical officer quoted in Managed Healthcare Executive. That's a different number than 20% of plans, and it doesn't tell you whether your specific employer benefit does. Foundayo (orforglipron) was FDA-approved April 1, 2026; its placement on your specific Prime formulary needs to be verified in your own portal.
If your plan covers anti-obesity GLP-1s, the best one to start with depends on what you and your prescriber want clinically — not on which drug is most famous. If you don't know yet whether your plan covers anything, that's the first thing to fix, and it takes about two minutes.
| First thing to verify | Best if you want | The biggest catch |
|---|---|---|
| Zepbound | Weight-loss or OSA route, and your plan covers anti-obesity meds | Prior auth and benefit exclusion still decide |
| Wegovy | Semaglutide route, cardiovascular-risk route, or your plan lists Wegovy more clearly | Formulation and indication matter |
| Foundayo | Oral-first FDA-approved route | Prime formulary placement must be verified in your plan |
Check your specific plan in about two minutes — free, no membership.
Ro's GLP-1 Insurance Coverage Checker contacts your insurer directly and sends you a personalized coverage report for Wegovy, Zepbound, Foundayo, Ozempic, and Mounjaro before you commit to anything.
Check my Prime plan's coverage on Ro → (sponsored affiliate link, opens in a new tab)Free; no prescription or membership required to run the checker
What We Actually Verified for This Page
We don't want you to trust us on faith. Here's exactly what we checked, with sources you can open yourself.
| Verified item | Source checked | Last checked | What it proves |
|---|---|---|---|
| Prime reports parity coverage for Wegovy and Zepbound for weight loss, in tier 3 or tier 4; about 20% of covered lives are in a benefit plan that covers weight loss | Managed Healthcare Executive PBM formulary article | May 11, 2026 | Prime treats Wegovy and Zepbound as peers; weight-loss benefit isn't universal |
| Wegovy injection, Wegovy tablets, and Zepbound auto-injectors appear in Prime-administered formulary documents with prior-authorization and dispensing-limit indicators | Multiple 2026 MyPrime drug guides (BCBSAL April 2026; HCSC 2026; others) | May 11, 2026 | Wegovy and Zepbound are listed; specific tier and group rules vary |
| Prior-authorization criteria pulled from Prime program summaries | HCSC Weight Management PAQL Program Summary (03-15-2026); BCBSND GLP-1 Agonists PAQL (01-01-2026); Choice Weight Management PA Form (04/2025); University of Michigan Clinical Criteria (04-17-2026) | May 11, 2026 | What plans typically require, with plan-by-plan variation |
| Foundayo FDA approval date (April 1, 2026) and Lilly Self-Pay Savings Card terms | Eli Lilly investor release; foundayo.lilly.com/coverage-savings | May 11, 2026 | Foundayo is FDA-approved; self-pay tiers and savings-card limits |
| Ro Body pricing and FDA-approved formulary | ro.co/weight-loss/pricing | May 11, 2026 | Pricing and which FDA-approved GLP-1s Ro carries |
| Medicare GLP-1 Bridge eligibility products and operation | CMS Medicare GLP-1 Bridge page | May 11, 2026 | Bridge operates outside normal Part D flow; eligible drugs and $50 copay |
What Is the Best FDA-Approved GLP-1 on Prime Therapeutics Formulary?
The honest answer.
The best FDA-approved GLP-1 on Prime Therapeutics formulary is the one your specific plan covers, your prescriber can justify, and you can stay on long-term. For weight loss, that's usually Zepbound or Wegovy — Prime treats them at parity on its national formularies. For an oral-first FDA-approved option, Foundayo, with the caveat that formulary placement is plan-specific. For type 2 diabetes, Ozempic, Mounjaro, or Rybelsus through the easier diabetes-coverage path.
The Prime Therapeutics FDA-Approved GLP-1 Coverage Matrix
Prime-administered formularies and program summaries include multiple FDA-approved GLP-1 paths. Not every plan covers every drug, indication, or formulation. Treat Wegovy and Zepbound as the first weight-loss coverage checks; treat Foundayo as plan-specific until it appears in your own portal.
| Brand (Generic) | FDA-approved for | Verified Prime signal (2026) | What can block coverage | Best question to ask |
|---|---|---|---|---|
| Wegovy injection (semaglutide pen) | Chronic weight management; cardiovascular risk reduction; MASH in adults with moderate-to-advanced fibrosis | Listed in multiple 2026 Prime-administered drug guides with prior-auth and dispensing-limit flags; parity with Zepbound at tier 3 or 4 nationally; one April 2026 guide listed it at Tier 2 with PA | PA criteria, plan exclusion, step therapy | "Is Wegovy injection covered for my diagnosis under my pharmacy benefit, and what PA criteria apply?" |
| Wegovy tablet 25 mg (oral semaglutide) | Chronic weight management (FDA-approved December 22, 2025) | Listed in some 2026 Prime-administered drug guides with PA/dispensing-limit indicators | PA criteria, newer-formulation coverage lag | "Is the Wegovy 25 mg tablet covered separately from the pen, and is it subject to PA?" |
| Zepbound (tirzepatide pen + KwikPen) | Chronic weight management; moderate-to-severe OSA in adults with obesity | Listed in multiple 2026 Prime-administered drug guides with PA/dispensing-limit flags; parity with Wegovy nationally; tier varies by plan | PA criteria, plan exclusion, step therapy | "Is Zepbound covered for obesity or OSA, and what PA criteria apply?" |
| Foundayo (orforglipron, oral, any time of day) | Chronic weight management (FDA-approved April 1, 2026) | Prime formulary placement must be verified in your own plan portal. Prime's April 2026 pipeline noted the approval; newly marketed drugs may not be covered until P&T review | Plan placement lag, PA criteria | "Is Foundayo on my plan's current formulary, and is it covered for chronic weight management?" |
| Saxenda (liraglutide, daily injection) | Chronic weight management (adults; adolescents 12–17) | Appears in Prime-administered weight-loss category materials with PA/QL; on some plans Saxenda has preferred status | PA criteria, daily-injection adherence | "Is Saxenda preferred or required as step therapy before Wegovy or Zepbound on my plan?" |
| Ozempic (semaglutide injection) | Type 2 diabetes; CV risk reduction in T2DM with CVD; diabetic nephropathy | Appears in Prime GLP-1 PA/QL program materials | PA criteria; not approved for weight loss — covered for T2DM | "Is Ozempic covered for my diagnosis, and is it being requested for an FDA-labeled indication?" |
| Mounjaro (tirzepatide injection) | Type 2 diabetes in adults and children 10+ (MACE risk-reduction indication is pending; not FDA-approved as of May 11, 2026) | Appears in Prime GLP-1 PA/QL program materials | PA criteria; not approved for weight loss | "Should my clinician request Mounjaro for diabetes, or Zepbound for weight management or OSA?" |
| Rybelsus (oral semaglutide) | Type 2 diabetes; MACE risk reduction (label updated October 2025) | Appears in Prime GLP-1 PA/QL program materials | PA criteria; T2DM only | "Is Rybelsus covered for my diagnosis under the diabetes benefit?" |
Amber row = Foundayo (newly approved; formulary placement varies by plan). Tier placement varies by employer and group. Always confirm on MyPrime or BlueAccess for your specific plan.
Don't want to read seven drug breakdowns?
Ro's free Coverage Checker pulls your specific plan's status in about two minutes — no membership, no commitment, no prescription required.
Run the free coverage check → (sponsored affiliate link, opens in a new tab)“On the Formulary” Doesn't Mean “Covered” — the Most Expensive Misunderstanding in GLP-1 Access
Most people who land on this page made the same mistake — they saw Wegovy on a PDF, told their doctor to write the prescription, and then got hit with a $1,200 cash price at the pharmacy. The drug was on the formulary. It just wasn't covered for them.
The five words you need to keep straight
The first question to ask is not “Is GLP-1 covered?”
It's:
- 1Is this specific brand and formulation covered for my diagnosis?
- 2Is the restriction PA, QL, step therapy, specialty pharmacy, or a flat benefit exclusion?
- 3Is weight management itself even a covered benefit under my employer's plan?
- 4What exact documentation does the PA require?
- 5What's my estimated copay after deductible?
Ask those five questions in order before you do anything else. They take a 5-minute phone call to your member services line. Most people skip them and pay for it in lost weeks.
The Prime portal status decoder
Pick the status your MyPrime or BlueAccess portal shows you, and act accordingly.
| What your portal says | What it usually means | Your best next move |
|---|---|---|
| Tier shown, no flag | Drug is listed; usually covered if you have the benefit | Confirm with member services that your employer plan covers the category for your diagnosis |
| PA required | Not denied — just not submitted yet | Get your prescriber to submit the PA with full BMI, comorbidity, lifestyle, and prior-trial documentation |
| QL (quantity limit) | The plan caps your fills | Ask for the allowed quantity; request a QL exception if you need more |
| ST (step therapy) | Plan wants you to try another drug first | Document the prior trial(s) or request a step-therapy medical exception |
| Non-formulary | The drug isn't on your specific plan's list | Request a formulary exception with a Letter of Medical Necessity |
| Benefit exclusion | The category isn't covered at all under your employer plan | Pursue documented secondary indication (CV for Wegovy, OSA for Zepbound, T2DM for Ozempic/Mounjaro), employer appeal, or self-pay |
| Tier shown but pharmacy claim rejected | Either a PA hasn't been submitted, a quantity issue, or an employer carve-out | Call member services for the exact rejection code; don't accept "not covered" over the phone as final |
Is Your Plan Even Administered by Prime Therapeutics?
Prime Therapeutics is a pharmacy benefit manager that serves about 40 million members through 33 health plans, including many of the largest Blue Cross Blue Shield plans. If your pharmacy ID card says “MyPrime,” “BlueAccess,” or names one of the plans below, you're likely on Prime.
Plans Prime Therapeutics publicly lists as clients
Several BCBS plans actually have ownership interests in Prime Therapeutics — Prime is privately held by 19 not-for-profit health plans, which is part of why its approach can differ from PBMs owned by larger insurers.
Which Prime formulary does your plan use?
Your formulary type is usually printed on your ID card or shown in MyPrime once you log in. If you can't find it, the number on the back of your card will tell you in 30 seconds.
Which FDA-Approved GLP-1 Should You Verify First?
“Best” depends on your diagnosis and your plan, not on which drug is most famous. Here's each option, who it's the best first verification for, and when to check something else.
Zepbound (tirzepatide): the strongest first verification for weight-loss searchers
Zepbound is the first medication to ask your prescriber about and verify on your plan if your plan covers anti-obesity GLP-1s and your clinician thinks tirzepatide is the right fit. Three reasons:
- 1Prime gives Zepbound parity with Wegovy. Unlike CVS Caremark, which removed Zepbound from its Standard Control, Advanced Control, and Value formularies effective July 1, 2025, Prime treats Wegovy and Zepbound as peers nationally. You're not pre-routed.
- 2The OSA indication is a real second pathway. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. If you've ever had a sleep study showing an apnea-hypopnea index of 15 or higher, your prescriber can ask the plan to evaluate Zepbound under the OSA criteria instead of the weight-management criteria.
- 3The GIP/GLP-1 dual mechanism has shown higher peak weight-loss percentages in published clinical trials. The SURMOUNT trials reported average weight loss of approximately 20–21% at higher Zepbound doses; the STEP trials reported approximately 15% at the highest Wegovy dose.
Wegovy (semaglutide): the strongest alternate and best semaglutide path
Wegovy is the right first verification when semaglutide is preferred clinically, when Wegovy is more clearly listed on your specific formulary, or when cardiovascular risk reduction is the documented reason. Wegovy now exists as both an injection pen and a once-daily 25 mg oral tablet (FDA-approved December 22, 2025).
The cardiovascular indication is the underrated lever. Wegovy injection is FDA-approved to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease. On plans that exclude weight-loss medications but cover cardiovascular medications, documenting established CVD can change which PA criteria your prescriber asks the plan to apply. Wegovy injection also carries an FDA-approved indication for MASH in adults with moderate-to-advanced liver fibrosis.
Foundayo (orforglipron): the oral-first FDA-approved option to verify
FDA-approved April 1, 2026, Foundayo is Lilly's oral orforglipron tablet for chronic weight management. Lilly describes it as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. (Wegovy's 25 mg oral tablet was FDA-approved December 2025 — Foundayo isn't the first oral GLP-1 weight-loss pill, it's the only one without timing-and-food restrictions.) Foundayo is a small-molecule drug rather than a peptide, which is why your body can absorb it through a standard tablet.
Self-pay pricing through LillyDirect (matched by Ro): $149/month for 0.8 mg, $199/month for 2.5 mg, $299/month for 5.5–17.2 mg (purchase-offer program), up to $349/month outside the purchase-offer program. With covered commercial insurance and the Lilly Savings Card, copay can drop to as low as $25/month, capped at $1,000/year, with the card expiring 12/31/26.
Saxenda (liraglutide): the legacy weight-loss path
Saxenda is the older daily-injection GLP-1 for weight management. On some Prime plans (notably HCSC), Saxenda has preferred status, which can mean it's approved more readily — though many patients prefer weekly injections to daily. Generic liraglutide for weight management was FDA-approved in August 2025.
Best first verification if: You have an adolescent patient (12–17) where Saxenda's pediatric indication matters, or your specific plan lists Saxenda as the preferred or step-therapy first option.
Ozempic, Mounjaro, Rybelsus: the diabetes paths
These three are FDA-approved for type 2 diabetes, not weight loss. Don't try to get them covered for weight loss — that's not what they're labeled for, and Prime's PA criteria will reject it. But if you have documented type 2 diabetes (or qualifying A1c ≥6.5%), they're typically the easier-coverage path because they sit on the diabetes side of the formulary.
Already know which drug you want?
Ro's insurance concierge handles prior-authorization paperwork end-to-end alongside your prescriber. Ro carries Foundayo, Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, and eligible insurance GLP-1s. Get started for $39 the first month, then as low as $74/month with annual plan paid upfront — medication cost is separate from membership.
See Ro's GLP-1 program → (sponsored affiliate link, opens in a new tab)Wegovy vs. Zepbound on Prime: Why You May Have a Real Choice
Effective July 1, 2025, CVS Caremark removed Zepbound from its Standard Control, Advanced Control, and Value formularies. Prime members don't have that exclusion baked in. That said — your individual plan can still flip the script. The University of Michigan/Prime plan's criteria, updated April 17, 2026, actually require a 12-week Zepbound trial before Wegovy. So “parity nationally” doesn't mean “no step therapy at your specific employer.” Always check your plan's PA form.
Side-by-side: when each one wins
| Factor | Wegovy | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide (GLP-1 agonist) | Tirzepatide (GIP + GLP-1 dual agonist) |
| Dosing | Once-weekly injection, or 25 mg oral tablet once daily | Once-weekly injection |
| Average weight loss at top dose in trials | ~15% body weight (STEP trials) | ~20–21% body weight (SURMOUNT trials) |
| Notable secondary indications | Cardiovascular risk reduction; MASH (injection only) | Obstructive sleep apnea (AHI ≥15) in adults with obesity |
| Prime national signal | Parity with Zepbound; tier varies by plan | Parity with Wegovy; tier varies by plan |
| Best when… | Semaglutide preferred clinically; CV pathway may apply; oral pill desired | Higher peak weight loss desired; documented OSA; plan covers anti-obesity meds |
| Watch out for | Some plans (like UMich) require Zepbound trial before Wegovy | Some plans require <52 weeks on max-tolerated dose at renewal |
What Does Prime Therapeutics Usually Require for GLP-1 Prior Authorization?
These criteria come from Prime's published program summaries — specifically the HCSC Weight Management PAQL Program Summary (effective March 15, 2026), the Choice Weight Management PA Form (revised April 2025), the BCBSND GLP-1 Agonists PAQL Summary, and the BCBS Kansas Weight Loss Agents PAQL Summary.
Typical initial PA elements (verified across multiple plans)
- 1Adult or adolescent age range matching FDA labeling — Wegovy and Zepbound for adults 18+; Wegovy and Saxenda for adolescents 12–17 with specific criteria
- 2BMI threshold — FDA labeling uses BMI ≥30 or BMI ≥27 with comorbidity; specific plans can be stricter
- 3For Wegovy specifically on many plans: patient does NOT have a history of type 2 diabetes, and current A1c is <6.5%, with medical records documenting A1c obtained within the previous 6 months
- 4Weight-related comorbidities — hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, or OSA
- 5Documented lifestyle modification — diet and exercise, typically 3–6 months
- 6No personal or family history of medullary thyroid carcinoma, MEN 2, or other FDA-labeled contraindications
- 7No history of pancreatitis on some plans for Wegovy and Zepbound
- 8Will NOT be used in combination with another GLP-1 receptor agonist
- 9Step therapy on some plans — documented trial and failure of one or more covered weight-loss agents (Contrave, phentermine, Qsymia, Xenical, or Saxenda) before Wegovy or Zepbound
Renewal authorization: the weight-loss documentation rule
Continuation of therapy on Prime typically requires documented weight loss from baseline. Practical implications:
A real worked example: the University of Michigan / Prime plan (revised April 17, 2026)
Initial-request adult weight-management criteria include:
- •Member does NOT have a history of type 2 diabetes
- •Member's current A1c is <6.5% (with chart notes documenting A1c within the previous 6 months)
- •BMI ≥35, OR BMI ≥27 with at least one listed risk factor (this is stricter than FDA labeling)
- •For Wegovy specifically: documented trial of 12 weeks of Zepbound first (yes — UMich runs Zepbound-before-Wegovy, the opposite of CVS Caremark)
- •Step-therapy documentation
- •Initial coverage duration: 16 weeks
- •Continuation: up to 24 months if criteria are met
Comparison across Prime-administered criteria sets
| Source / plan | BMI threshold | A1c rule for Wegovy | Step therapy required | Initial approval length |
|---|---|---|---|---|
| Most Prime national templates | ≥30, or ≥27 with comorbidity | Often required (no T2DM history; A1c <6.5%) | Plan-dependent (Contrave, phentermine, Qsymia, or Xenical typical) | 12 months on many plans |
| University of Michigan (Prime-administered, revised 04/17/26) | ≥35, or ≥27 with listed risk factor | Required (no T2DM; A1c <6.5%) | 12-week Zepbound trial required before Wegovy | 16 weeks initial; up to 24-month continuation |
| Saxenda pediatric (Prime templates) | BMI at or above 95th percentile for age and sex | N/A | Varies | 5 months pediatric; 4 months adult |
What Safety or Eligibility Issues Can Change the GLP-1 Answer?
Coverage isn't the only decision. GLP-1 medications are prescription drugs, and the right route can change based on medical history, current medications, pregnancy plans, history of medullary thyroid carcinoma or MEN 2, pancreatitis history, kidney or gallbladder issues, diabetic retinopathy, surgery, and clinician judgment.
Use this page to verify the coverage path. Use your clinician for the medical-fit decision.
How Much Will Wegovy, Zepbound, or Foundayo Cost If Prime Does Not Cover It?
What your copay could look like with coverage
Copay examples are plan-specific. In Prime-administered drug guides we checked, Wegovy and Zepbound appear with prior authorization and dispensing-limit indicators, but your actual copay depends on your benefit booklet, deductible, and your employer's coverage election. Most Prime-administered plans use either a 4-tier or 6-tier copay structure with tier 3 typically being preferred brand and tier 4 non-preferred brand. Always confirm your specific plan's copay structure via MyPrime or BlueAccess.
Manufacturer savings cards that may stack with Prime coverage
Cash-pay reality if your plan doesn't cover GLP-1s
Remember: only about 20% of Prime covered lives are in benefit plans that cover weight-loss medications. Here are verified published self-pay prices for 2026:
| Medication path | Verified self-pay price | Notes |
|---|---|---|
| Wegovy pill 1.5 mg or 4 mg | $149/month | NovoCare; 4 mg offer changes after Aug. 31, 2026 |
| Wegovy pill on Ro | $149 first month; $199–$299/month thereafter | Ro matches LillyDirect/NovoCare pricing |
| Wegovy pen (new patients via NovoCare) | $199/month for first two fills, then $349/month | For 2.4 mg dose; offer through June 30, 2026 |
| Wegovy HD (7.2 mg) | $399/month | NovoCare |
| Zepbound KwikPen via Ro (Lilly purchase offer) | $299–$449/month by dose | $299 for 2.5 mg; $399 for 5 mg; $449 for 7.5–15 mg; 45-day refill window required |
| Zepbound KwikPen via Ro (offer window missed) | $499–$699/month | $499 for 7.5 mg; $699 for 10, 12.5, and 15 mg |
| Foundayo 0.8 mg | $149/month | LillyDirect self-pay (matched by Ro) |
| Foundayo 2.5 mg | $199/month | LillyDirect self-pay (matched by Ro) |
| Foundayo 5.5–17.2 mg | $299–$349/month | Purchase-offer program ($299) or up to $349 outside it |
| Ro Body membership | $39 first month, then $149/month | Or as low as $74/month with annual plan paid upfront — separate from medication cost |
| Sesame Care GLP-1 program | As low as $59/month annually | Costco-member pricing available for Wegovy and Ozempic; medication separate |
If Your GLP-1 Is Denied, Excluded, or “Non-Formulary”: the Appeal Playbook
1Get the denial reason in writing
Don't accept “it's not covered” over the phone as final. Ask explicitly:
“Can you tell me the exact denial code or reason, and can you mail or email me the written denial notice with the specific PA criteria I didn't meet?”
If they refuse, escalate to a supervisor. Your denial notice should explain why the request was denied and what appeal or exception rights apply under your plan.
2File a formulary exception or internal appeal
Documentation checklist (your prescriber's office handles this — knowing what they need helps):
- ✓Current BMI calculation and matching ICD-10 diagnosis code (E66.x for obesity)
- ✓Comorbidities with ICD-10 codes (I10 hypertension, E78.5 dyslipidemia, E11.x type 2 diabetes, G47.33 OSA, I25.x established CVD)
- ✓3–6 months of documented lifestyle modification (diet, exercise, behavioral effort — chart notes)
- ✓Prior medication trial records (if step therapy applies)
- ✓A prescriber-signed Letter of Medical Necessity explaining why this specific drug is needed and why alternatives won't work
3External review
If your internal appeal is upheld and you still want to fight, federal law gives most patients the right to an external independent review. Your denial notice will explain your specific external-review rights and timelines.
4Don't lose months waiting for paperwork
Appeals can take weeks to months. If you've been prescribed a GLP-1 and your prescriber thinks you genuinely need it, two options to bridge:
Stuck in PA denial limbo?
Ro's insurance concierge can pick up appeal paperwork mid-process, and you can start a self-pay Wegovy, Zepbound, or Foundayo prescription through licensed clinicians at LillyDirect-match pricing while the appeal continues. If your appeal succeeds, you switch back to insurance.
See Ro's GLP-1 program → (sponsored affiliate link, opens in a new tab)Ro Body: $39 first month, then $149/month, or as low as $74/month with annual plan; medication separate
Should You Use Ro, Sesame Care, Your Regular Doctor, or MyPrime First?
| Route | Best for | Strength | Limitation |
|---|---|---|---|
| Your regular prescriber | Clear coverage, established relationship, complex medical history | Knows your chart; documents comorbidities precisely; no extra service fee | May not aggressively fight denials or know which exception strategies work |
| MyPrime / BlueAccess portal | Verifying tier, PA, QL, step therapy, exclusion | Direct source of plan-specific facts | Doesn't prescribe or build a treatment plan |
| Ro | Prime members who want insurance coverage checked plus FDA-approved GLP-1 telehealth | Free Coverage Checker contacts your insurer and sends a personalized report; insurance concierge handles PA paperwork; FDA-approved formulary including Foundayo, Wegovy pill, Wegovy pen, Zepbound pen, and Zepbound KwikPen; matches LillyDirect / NovoCare pricing | Ro Body membership is separate from medication cost ($39 first month, then $149/month or $74/month with annual plan); Ro states it cannot coordinate GLP-1 coverage for government insurance plans |
| Sesame Care | Brand-name self-pay shopping, provider choice, Costco-member pricing | Program as low as $59/month annually; FDA-approved GLP-1 options; published price visibility | Medication cost separate; less concierge-style PA handling |
Why we recommend Ro as the primary route on this page
Ro is our primary recommendation on this page because this search is insurance-sensitive and prior-authorization heavy, and Ro publishes a free coverage checker, insurance-concierge support, and FDA-approved brand-name GLP-1 access in one route. You don't need a prescription or a Ro membership to run the Coverage Checker — Ro's insurance specialists actually contact your insurer and send a personalized coverage report.
The honest damaging admission
Ro is not automatically the cheapest path if your existing prescriber will handle the PA for you and your plan clearly covers your GLP-1. If your doctor is responsive, your copay is reasonable, and your only obstacle is paperwork your office will file anyway, sticking with your existing prescriber is straightforwardly cheaper — there's no Ro Body membership cost layered on top.
If that's you: log into MyPrime, confirm coverage, take the printed coverage details to your doctor's appointment, and ask them to file the PA. Done. We'd rather you save the money than feel pressured to add a service you don't need.
Want to check your specific coverage before committing to anything?
Ro's GLP-1 Insurance Coverage Checker is free, takes about two minutes, and tells you what your plan actually does for Wegovy, Zepbound, Foundayo, Ozempic, and Mounjaro — no membership required.
Run the free coverage check → (sponsored affiliate link, opens in a new tab)For Costco-member angles or provider-choice browsing, Sesame Care is worth a look:
Compare FDA-approved branded GLP-1 pricing on Sesame Care → (sponsored affiliate link, opens in a new tab)Program as low as $59/month annually; medication separate
How to Verify Your Specific Prime Therapeutics GLP-1 Coverage (3-Step Workflow)
The fastest order: Log into MyPrime or BlueAccess. Search the exact brand and formulation. Call member services if anything is ambiguous. If you don't want to log in, run Ro's free Coverage Checker — it pulls the same info without an account.
1Log into MyPrime or your insurer's portal
Look for “Pharmacy,” “Prescription Drug Coverage,” or “Drug Lookup.” On BCBSIL, BCBSTX, BCBSMT, BCBSNM, and BCBSOK, this is in BlueAccess for Members. On Florida Blue, look under “My Plan → Pharmacy Resources → Compare Drug Pricing.” On Horizon BCBSNJ, use the Horizon member portal and look for the pharmacy benefits or drug-lookup section.
2Search the exact brand AND formulation
Don't just search “Wegovy.” Search Wegovy pen 2.4 mg or Wegovy tablet 25 mg or Zepbound KwikPen or Foundayo 0.8 mg. Formulations matter — Wegovy pen and Wegovy tablet can have different tier placements and PA criteria on the same plan.
For each medication you check, record:
3Call member services for anything ambiguous
The number is on the back of your ID card. Use this script verbatim:
“Hi, I'm trying to verify coverage for an FDA-approved GLP-1 medication under my pharmacy benefit. Specifically [Wegovy / Zepbound / Foundayo / etc.] in [formulation and dose]. Can you check: (1) is this drug covered for my diagnosis of [obesity / overweight with comorbidity / type 2 diabetes / OSA], (2) is the restriction prior authorization, quantity limit, step therapy, non-formulary status, or a benefit exclusion, (3) does my employer plan include weight-management medications as a covered benefit, (4) what's the written PA criteria I should give my prescriber, and (5) what's my estimated copay after deductible?”
Get the rep's name. Get a reference number for the call. Write down what they tell you. If they can't answer, escalate or call back.
Or skip the phone call
Run Ro's free GLP-1 Insurance Coverage Checker → (sponsored affiliate link, opens in a new tab)Ro's insurance specialists contact your insurer and send a personalized coverage report. No prescription required.
Real Prime Members on Coverage Friction
The frustrating part for most people isn't understanding GLP-1s. It's the limbo. Here's how Prime members describe the experience in their own words:
“Wegovy is listed as an approved med in their formulary (with a PA)… since then it's been crickets.”
“Zepbound was a plan exclusion…”
“Does anyone have insight on getting this exclusion overturned?”
“I don't know WHAT to ask…”
The Bottom-Line Decision Tree
If you only read one section, read this one.
Do you have type 2 diabetes (or A1c ≥6.5%)?
→ Ask your prescriber about Ozempic, Mounjaro, or Rybelsus first. The diabetes path on Prime is typically easier coverage with lighter PA.
Are you seeking weight-loss treatment, and does your plan cover anti-obesity GLP-1s?
→ Verify Zepbound and Wegovy with your prescriber. Both at parity on Prime nationally. Pick based on clinical fit, not formulary preference.
Do you strongly prefer a pill?
→ Verify Foundayo (treat as plan-specific — most Prime plans hadn't placed it by mid-2026) and Wegovy tablet (25 mg, FDA-approved December 2025).
Does your plan portal show "PA required"?
→ That's not a denial. Get your prescriber to submit it with full documentation: BMI, comorbidities with ICD-10 codes, lifestyle modification history, and any prior medication trials.
Does your plan say "non-formulary" or "benefit exclusion"?
→ Different problem. For non-formulary, request a formulary exception with a Letter of Medical Necessity. For benefit exclusion (weight-loss meds excluded entirely), explore a documented secondary indication (CV for Wegovy injection, OSA for Zepbound, T2DM for Ozempic/Mounjaro), employer appeal, or self-pay through Ro or LillyDirect.
Are you still not sure what to do?
→ Take our free 60-second matching quiz and we'll build you a personalized action plan.
Frequently Asked Questions
Does Prime Therapeutics cover Wegovy in 2026?
Some Prime-administered formularies list Wegovy (injection and 25 mg tablet) with prior authorization and quantity limits. But formulary listing doesn't guarantee your specific plan covers it — only about 20% of Prime covered lives are in benefit plans that cover weight-loss medications. Check your specific plan on MyPrime or run Ro's free Coverage Checker.
Does Prime Therapeutics cover Zepbound in 2026?
Yes, on plans that cover weight-loss GLP-1s, Zepbound (pen and KwikPen) is typically listed with prior authorization. Prime treats Wegovy and Zepbound at parity nationally — neither is "preferred" over the other — which is different from CVS Caremark, which removed Zepbound from several formularies effective July 1, 2025. Your specific plan still decides.
What tier are Wegovy and Zepbound on Prime Therapeutics?
Tier placement is plan-specific. Per Managed Healthcare Executive, Prime reports parity coverage for Wegovy and Zepbound at tier 3 or tier 4 nationally for weight loss. One April 2026 Prime-administered drug guide listed them at Tier 2 with prior authorization and dispensing-limit indicators. Verify your specific plan's tier in your portal.
Does Prime Therapeutics cover Foundayo (orforglipron)?
Foundayo was FDA-approved April 1, 2026. Prime's April 2026 pipeline noted the approval, but because Foundayo is newly marketed, individual Prime plan placement is rolling and must be verified in your own portal. Prime drug-guide language generally notes that newly marketed drugs may not be covered until P&T Committee review.
Does Prime Therapeutics require prior authorization for Ozempic?
Yes. Prime requires prior authorization for Ozempic when prescribed for type 2 diabetes, with criteria including documented A1c, attempted lifestyle modification, and often step therapy with metformin or another agent first. The diabetes PA path is typically lighter than the weight-loss PA path.
What BMI does Prime Therapeutics require for Wegovy coverage?
FDA labeling uses BMI ≥30, or BMI ≥27 with a weight-related condition. Plan-specific Prime PA criteria can be stricter. The University of Michigan/Prime plan requires BMI ≥35, or BMI ≥27 with listed risk factors, plus no history of type 2 diabetes and A1c <6.5%. Check your specific plan's PA form.
How long does Prime Therapeutics take to approve a GLP-1 prior authorization?
PA review timing varies by plan and request type. Ask member services for the routine and urgent review timelines specific to your plan. Complete documentation at the time of submission is the biggest factor in fast approval. Incomplete forms get returned for more information.
What if Prime Therapeutics denies my GLP-1?
First, identify the denial type. "PA required" isn't a denial. "PA denied" means documentation didn't meet criteria — get the denial letter, fix the gap, resubmit. "Non-formulary" means request a formulary exception with a Letter of Medical Necessity. "Benefit exclusion" means the category isn't covered at all — pursue secondary-indication strategies or self-pay through Ro or LillyDirect.
Can I appeal a Prime Therapeutics GLP-1 denial?
Yes. You're entitled to an internal appeal, and federal law gives most patients the right to an external independent review under certain plan types. Strong appeals include a prescriber-signed Letter of Medical Necessity, full BMI and comorbidity documentation with ICD-10 codes, documented lifestyle modification, and any prior medication trial records.
Does Prime Therapeutics cover compounded semaglutide or tirzepatide?
This page covers FDA-approved GLP-1 medications. FDA states compounded drugs are not FDA-approved. Prime-administered drug guides vary — at least one April 2026 guide indicates compounded drugs may be covered when medically necessary, subject to review, may require prior authorization, and must not be a copy of a commercially available product. Check your specific plan before assuming coverage or exclusion.
Is Saxenda preferred over Wegovy on Prime Therapeutics?
On some Prime-administered plans (notably HCSC), Saxenda has preferred status while Wegovy may be non-preferred. This means Saxenda may be approved more readily, while Wegovy may require step therapy or stronger documentation. Always check your specific plan.
Does Medicare Part D administered by Prime cover Foundayo?
Beginning July 1, 2026, eligible Medicare Part D beneficiaries may access Foundayo through the Medicare GLP-1 Bridge, which CMS says operates outside the normal Part D coverage and payment flow. CMS lists Foundayo, Wegovy injection, Wegovy tablets, and Zepbound KwikPen as eligible Bridge products. Beneficiaries must meet Bridge prior-authorization criteria, and pharmacies collect a $50 copay for eligible claims.
How We Built This Guide (Methodology)
We are The RX Index, a pricing intelligence and comparison resource for GLP-1 telehealth providers. To build this guide, our editorial team did three things.
Author and editorial standards
This guide was written and edited by The RX Index editorial team. We do not add “medically reviewed by” unless a qualified clinician has reviewed the page. We are not a medical practice and we do not provide medical advice. Information on this page is for educational purposes and should not replace consultation with a licensed clinician.
Affiliate disclosure
The RX Index earns affiliate commissions from some of the GLP-1 providers mentioned in this guide, including Ro and Sesame Care. We do not earn commissions from Prime Therapeutics, Eli Lilly, Novo Nordisk, or any BCBS plan. Ro is our primary recommendation on this page because this search is insurance-sensitive and prior-authorization heavy, and Ro publishes a free coverage checker, insurance-concierge support, and FDA-approved brand-name GLP-1 access in one route.
What we keep updated
We re-verify formulary placements monthly through 2026 for Foundayo (as plans add it), quarterly for Wegovy and Zepbound tier placements, monthly for Ro pricing and Lilly Savings Card terms (the Foundayo card expires 12/31/26), and quarterly for the Prime-administered plan list. The “Last verified” date at the top of this page is updated every time we touch the content.
Still Not Sure Which GLP-1 Path Is Right for You?
Insurance, PA criteria, exclusions, step therapy, denial codes, formulary tiers — it's a lot, and you're trying to make a real health decision in the middle of it. We built a 60-second matching tool for you — answer six quick questions about your situation and get a single-page action plan with your best first verification path, the exact questions to ask your prescriber, and which provider route fits your situation best.
60-second quiz is free, no signup required. Ro Coverage Checker: free, no prescription or membership required.